

Financial news for AAVL dated on 2016-05-06: CytomX Therapeutics Reports Q1 EPS \$(0.57) vs. Est. \$(0.39), Rev. \$265K vs. Est. \$400K

Financial news for AAVL dated on 2016-04-21: Watch Small Cap Biotech Shares On Alimera Halts, Companies up 5% Or Higher On The Day Include Inotek Pharmaceuticals, Avalanch Biotech, Opththotech

Financial news for AAVL dated on 2016-03-15: Avalanche Biotechnologies Board Member Paul D. Wachter to Resign

Financial news for AAVL dated on 2016-03-03: Avalanche Biotechnologies Reports Q4 EPS \$(0.55) vs. Est. \$(0.53), Rev. \$1M vs. Est. \$400K

Financial news for AAVL dated on 2016-03-01: Chardan Capital Maintains Buy on Avalanche Biotechnologies, Lowers PT to \$9.00

Financial news for AAVL dated on 2016-02-01: Benzinga's M&A Chatter for Monday February 1, 2015

Financial news for AAVL dated on 2016-02-01: Avalance Biotechnologies Tumbles 14% Following Acquisition Announcement

Financial news for AAVL dated on 2016-02-01: Stocks Hitting 52-Week Lows

Financial news for AAVL dated on 2016-02-01: Avalanche Biotechnologies, Annapurna Therapeutics Announce Proposed Merger; Annapurna To Be Acquired For 17.6M Shares Of Avalanche Stock and Will Own 37.5% of Merged Company

Financial news for AAVL dated on 2016-01-21: Numeric Investors Reports 5.34% Stake In Avalanche Biotechnologies 13G Filing

Financial news for AAVL dated on 2015-11-20: Avalanche Biotechnologies, Inc. Names Paul B. Cleveland as CEO

Financial news for AAVL dated on 2015-11-16: 5 Biotechs That Can Win From Ophthalmology Innovation

Financial news for AAVL dated on 2015-11-09: Avalanche Biotechnologies Reports Q3 EPS \$(0.55) Vs Est (\$0.42)

Financial news for AAVL dated on 2015-09-13: Stocks Selling Below Cash Per Share And Debt Free: How To Profit

Financial news for AAVL dated on 2015-08-14: Another Landslide In Avalanche Biotech

Financial news for AAVL dated on 2015-08-14: Morning Market Losers

Financial news for AAVL dated on 2015-08-14: Benzinga's Top #PreMarket Losers

Financial news for AAVL dated on 2015-08-13: Avalanche Biotechnologies Reports Q2 EPS \$(0.38) vs. Est. \$(0.39), Rev. \$279K vs. Est. \$760K

Financial news for AAVL dated on 2015-07-27: Market Update: Top Analysts Comment On Avalanche, Whole Foods And Twitter

Financial news for AAVL dated on 2015-07-27: Chardan's Take On Axovant, Avalanche & VistaGen

Financial news for AAVL dated on 2015-07-23: Avalance Biotech CEO Dr. Thomas Chalberg Resigns, Names Hans P. Hull Interim CEO

Financial news for AAVL dated on 2015-07-23: Hans P. Hull Appointed Interim CEO and President of Avalanche Biotechnologies

Financial news for AAVL dated on 2015-06-23: Chardan Capital Upgrades Avalanche Biotechnologies to Neutral

Financial news for AAVL dated on 2015-06-19: Stocks Hitting 52-Week Lows

Financial news for AAVL dated on 2015-06-19: Watch These After-Hours Movers Today

Financial news for AAVL dated on 2015-06-16: Mid-Afternoon Market Update: Dow Surges Over 100 Points; Avalanche Biotechnologies Shares Dip Following Mixed AVA-101 Data

Financial news for AAVL dated on 2015-06-16: Avalanche Biotechnologies Buried By Disappointing Data, Downgrades

Financial news for AAVL dated on 2015-06-16: Mid-Day Market Update: Coty Jumps On Report of Deal With P&G; Tahoe Resources Shares Drop

Financial news for AAVL dated on 2015-06-16: Look Out Below In Avalanche Biotech

Financial news for AAVL dated on 2015-06-16: Mid-Morning Market Update: Markets Rise; FactSet Profit Beats Estimates

Financial news for AAVL dated on 2015-06-16: Stocks Hitting 52-Week Lows

Financial news for AAVL dated on 2015-06-16: Morning Market Losers

Financial news for AAVL dated on 2015-06-16: Benzinga's Top Downgrades

Financial news for AAVL dated on 2015-06-16: Suntrust Downgrades Avalanche Biotechnologies To Neutral

Financial news for AAVL dated on 2015-06-16: Benzinga's Top #PreMarket Losers

Financial news for AAVL dated on 2015-06-16: Chardan Capital Downgrades Avalanche Biotechnologies to Sell, Lowers PT to \$20.00

Financial news for AAVL dated on 2015-06-16: Avalanche Biotechnologies Shares Fall 48% Premarket Following Mixed AVA-101 Data; Analyst Downgrades

Financial news for AAVL dated on 2015-06-16: SunCoke Energy, Tuesday Morning, Avalanche Bio Worth Watching Heading Into The Open

Financial news for AAVL dated on 2015-06-16: US Stock Futures Decline Ahead Of Housing Starts Report

Financial news for AAVL dated on 2015-06-16: Avalanche Bio Downgraded At William Blair, Firm Says Phase IIb 'A Ways Away'

Financial news for AAVL dated on 2015-06-16: William Blair Downgrades Avalanche Biotech: Questions Lucentis Performance, 'Difficult Population Clouds Phase IIa,' Sees Phase IIb 'A Ways Away'

Financial news for AAVL dated on 2015-06-16: Suntrust Downgrades Avalanche Biotechnologies to Neutral

Financial news for AAVL dated on 2015-06-16: William Blair Downgrades Avalanche Biotechnologies to Market Perform

Financial news for AAVL dated on 2015-06-15: Adam Feuerstein @adamfeuerstein Tweet: \$AAVL -- Best I can guess an explanation for stock drop is control arm performed really badly. Plus, retinal thickness worsened w/ '101

Financial news for AAVL dated on 2015-06-15: UPDATE: Avalanche Shares Reverse and Fall as Low as \$22.50 Following Report of Positive Top-Line Phase 2a Results for AVA-101 in Wet Age-Related Macular Degeneration

Financial news for AAVL dated on 2015-06-15: UPDATE: Avalanche Shares Rise 33% After-Hours on Positive Top-Line Phase 2a Results for AVA-101 in Wet Age-Related Macular Degeneration

Financial news for AAVL dated on 2015-06-15: Avalanche Biotechnologies, Inc. Announces Positive Top-Line Phase 2a Results for AVA-101 in Wet Age-Related Macular Degeneration

Financial news for AAVL dated on 2015-06-11: Why Avalanche Biotechnologies Is Coming Off A Big Day

Financial news for AAVL dated on 2015-06-10: Avalanche Bio Shares Rise 5%; May be Attributed in Part to Earlier Street.com Article

Financial news for AAVL dated on 2015-05-13: Avalanche Biotechnologies Reports Q1 Loss \$0.38 Vs Exp Loss \$0.40, Sales \$203K

Financial news for AAVL dated on 2015-04-27: Gene Therapy Stocks Take Beating On Bad News For Celladon

Financial news for AAVL dated on 2015-04-06: 16 Biotech Catalysts SunTrust Is Tracking

Financial news for AAVL dated on 2015-03-25: US Stock Futures Flat Ahead Of Durable-Goods Orders Data

Financial news for AAVL dated on 2015-03-25: Avalanche Biotechnologies, U of Washington Enter Into Exclusive License Agreement to Develop Gene Therapy Medicines to Treat Color Blindness

Financial news for AAVL dated on 2015-03-10: SunTrust Robinson Humphrey Initiates Coverage on Avalanche Biotechnologies at Buy, Announces \$60.00 PT

Financial news for AAVL dated on 2015-03-05: Avalanche Biotech Reports Q4 EPS -\$0.46 Vs Est -\$0.29, Sales \$203K Vs Est \$430K

Financial news for AAVL dated on 2015-02-19: Benzinga's Top Initiations

Financial news for AAVL dated on 2015-02-19: Chardan Capital Initiates Avalanche Biotechnologies With Neutral

Financial news for AAVL dated on 2015-02-19: Chardan Capital Initiates Coverage on Avalanche Biotechnologies at Neutral, Announces \$40.00 PT

Financial news for AAVL dated on 2015-02-09: DigiSight Technologies Announces \$7.8M in Series B Financing

Financial news for AAVL dated on 2015-01-08: Avalanche Biotechnologies Prices 2.4M Share Offering at \$59/Share

Financial news for AAVL dated on 2015-01-07: 4 More Biotech Secondaries Investors Are Watching

Financial news for AAVL dated on 2015-01-05: Avalanche Biotechnologies Announces 2M Share Proposed Public Offering of Common Stock

Financial news for AAVL dated on 2014-12-18: S-1 from Avalanche Biotech Shows Registration for \$100M in Share Offering

Financial news for AAVL dated on 2014-11-17: Events for the Week of Nov. 17-21, 2014

Financial news for AAVL dated on 2014-09-23: Avalanche Biotechnologies, Inc., Appoints Industry Leader Roman G. Rubio, M.D., As Senior VP And Head Of Translational Medicine

Financial news for AAVL dated on 2014-08-25: Benzinga's Top Initiations

Financial news for AAVL dated on 2014-08-25: William Blair Initiates Coverage on Avalanche Biotechnologies, Inc. at Outperform

Financial news for AAVL dated on 2014-08-25: Piper Jaffray Initiates Avalanche Biotechnologies At Overweight

Financial news for AAVL dated on 2014-08-25: Piper Jaffray Initiates Coverage on Avalanche Biotechnologies, Inc. at Overweight, Announces \$39.00 PT

Financial news for AAVL dated on 2014-08-25: Cowen & Company Initiates Coverage on Avalanche Biotechnologies, Inc. at Outperform, Announces \$45.00 PT

Financial news for AAVL dated on 2014-08-25: Jefferies Initiates Coverage on Avalanche Biotechnologies, Inc. at Buy, Announces \$40.00 PT

Financial news for AAVL dated on 2014-08-05: Deerfield Management Reports 9.87% Passive Stake in Avalanche Biotechnologies as of Aug 5

Financial news for AAVL dated on 2014-08-04: IPO Outlook: Can A \$200 Million IPO Be The Answer After A Lackluster Week?

Financial news for AAVL dated on 2014-07-31: Avalanche IPO Opens at \$25/Share, Priced at \$17

Financial news for AAVL dated on 2014-07-31: Waiting on 11 IPOs This Morning

Financial news for AAVL dated on 2014-07-28: IPO Lookout: Busy Week Brings The Biggest IPO Since Facebook

Financial news for AAVL dated on 2014-07-21: Avalanche Biotechnologies Expects 5.4M Share IPO to Price \$13.00-\$15.00/Share